Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.33 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL574865 | 0.80 | CYP19A1 (0.32) | KIF11CYP19A1 | |
| SCHEMBL1502646 | 0.80 | CYP19A1 (0.31) | CYP19A1 | |
| SCHEMBL119711 | 0.79 | TRPV6 (0.39) | ALDH1A1 | |
| SCHEMBL454794 | 0.79 | — | — | |
| SCHEMBL12615910 | 0.78 | NPC1 (0.36) | ALDH1A1CYP1A2CYP3A4KIF11CYP11B1 | |
| SCHEMBL20600817 | 0.78 | CA4 (0.38) | ALDH1A1CYP1A2CYP3A4KIF11LMNA | |
| SCHEMBL532324 | 0.77 | KMT2A (0.36) | KMT2A | |
| SCHEMBL1935838 | 0.77 | PTGS2 (0.39) | ALDH1A1CYP1A2CYP3A4KIF11CYP11B1 | |
| SCHEMBL2270306 | 0.75 | ALDH1A1 (0.43) | ALDH1A1CYP1A2CYP3A4LMNACYP11B1 | |
| SCHEMBL8131766 | 0.75 | ALDH1A1 (0.41) | ALDH1A1CYP1A2CYP3A4LMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 343 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111004264-B | Preparation method of N-substituted tetrahydropyridine-3/4-boric acid/ester | 沧州普瑞东方科技有限公司 | 2022-05-17 | — | — | CN | claimed |
| CN-111349138-A | Method for preparing abiraterone acetate | 江苏恒瑞医药股份有限公司 | 2020-06-30 | — | — | CN | claimed |
| CN-111205269-A | Preparation method and application preparation of carbazole-based organic electrophosphorescent material composition | 上海百豪新材料有限公司 | 2020-05-29 | — | — | CN | claimed |
| CN-111004264-A | Preparation method of N-substituted tetrahydropyridine-3/4-boric acid/ester | 沧州普瑞东方科技有限公司 | 2020-04-14 | — | — | CN | claimed |
| CN-109705186-A | A kind of preparation method of Abiraterone acetate | 奥锐特药业股份有限公司 | 2019-05-03 | — | — | CN | claimed |
| CN-106532120-B | A kind of nonaqueous electrolytic solution and the lithium secondary battery using the electrolyte | 广州天赐高新材料股份有限公司 | 2019-02-01 | — | — | CN | claimed |
| US-9663550-B2 | Method for preparing abiraterone acetate | Wuhan Biocause Pharmaceutical Development Co., Ltd. (CN) | 2017-05-30 | — | — | US | claimed |
| US-20160237109-A1 | Method for Preparing Abiraterone Acetate | Wuhan Biocause Pharmaceutical Development Co., Ltd. (CN) | 2016-08-18 | — | — | US | claimed |
| CN-103951705-B | A kind of take carbazole as the bipolarity small molecule host material with butterfly-like shape and the preparation method of core | SOUTH CHINA UNIVERSITY OF TECHNOLOGY (CN) | 2016-04-13 | — | — | CN | claimed |
| US-12637442-B2 | Organic electronic material containing nitrogen atom heterocyclic ring, preparation method therefor and application thereof | Shanghai Chuanqin New Material Co., Ltd (CN) | 2026-05-26 | — | — | US | disclosed |
| CN-122036730-A | Gαq/11 protein inhibitor with purine skeleton, and preparation method and application thereof | 中山大学 | 2026-05-15 | — | — | CN | disclosed |
| EP-4741392-A1 | 1H-PYRAZOLO[4,3-C]PYRIDINE COMPOUND, AND COMPOSITION THEREOF AND USE THEREOF | Shenzhen TargetRx Co., Ltd. (CN) | 2026-05-13 | — | — | EP | disclosed |
| EP-4695236-A1 | SUBSTITUTED PHENYL-PIPERAZINYL BASED MODULATORS FOR THE TREATMENT OF DISEASE | Soley Therapeutics, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-4344702-B1 | PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2026-01-28 | — | — | EP | disclosed |
| US-7361763-B2 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| WO-2007106236-A2 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2007-09-20 | — | — | WO | disclosed |
| EP-1781654-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2007-05-09 | — | — | EP | disclosed |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | SGX PHARMACEUTICALS, INC. (US) | 2007-02-22 | — | — | US | disclosed |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | US | disclosed |
| WO-2006015123-A1 | PYRROLO-PYRIDINE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637442-B2 | Organic electronic material containing nitrogen atom heterocyclic ring, preparation method therefor and application thereof | EML4, CTNNA1, TCF7L2 | ALDH1A1 340/4885CYP1A2 761/4885CYP3A4 258/4885 |
| US-20160237109-A1 | Method for Preparing Abiraterone Acetate | NR5A1, HSD17B7, CYP17A1 | ALDH1A1 1029/4885CYP1A2 575/4885CYP3A4 530/4885 |
| US-20060030583-A1 | Pyrrolo-pyridine kinase modulators | MAP3K20, MAP4K2, MAP3K19 | ALDH1A1 4474/4885CYP1A2 4275/4885CYP3A4 3697/4885 |
| US-20070043068-A1 | to treat diseases mediated by kinase activity; for example: [3-(2-methoxy-phenyl)-1H-pyrrolo[2,3-b]pyridine-5-yl]-methyl-phenyl-amine | MAP3K20, MAP4K2, MAP3K6 | ALDH1A1 4281/4885CYP1A2 4330/4885CYP3A4 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.